-
Firm Masters greens make life hard on golf's finest
-
Defending champ McIlroy shares Masters lead after back-nine birdie run
-
After oil, Venezuela opens up mining to private investors
-
Tigers' Meadows in hospital after colliding with teammate
-
US to host Israel-Lebanon talks as strikes threaten Iran ceasefire
-
'Scrappy' McIlroy leans on experience for share of Masters lead
-
Ukraine and Russia will cease fire for Orthodox Easter
-
Mateta inspires Palace win over Fiorentina in Conference League
-
Pioneering US hip-hop artist Afrika Bambaataa dies at 68
-
Russia bans Nobel-winning rights group, raids independent newspaper, in one day
-
Pentagon denies giving Vatican envoy 'bitter lecture'
-
Watkins propels Villa towards Europa League semis, Forest hold Porto
-
Aston Villa on verge of Europa League semis after beating Bologna
-
Venezuela police clash with protesters demanding salary rises
-
CAF president rejects corruption claims by Senegal
-
Israel and Lebanon set for ceasefire talks next week, says US official
-
US stocks extend gains, shrugging off ceasefire worries
-
IMF chief urges nations to 'do no harm' in fiscal response to Iran war
-
Sixers' Embiid to have surgery for appendicitis - team
-
Russian police raid independent Novaya Gazeta outlet, reporter detained
-
Former heavyweight king Fury adamant 'I've still got it' as Makhmudov awaits
-
Shipping toll for Hormuz passage sharply divides nations
-
McIlroy's back-nine birdie run grabs share of Masters lead
-
Melania Trump blasts 'lies' linking her to Epstein
-
'Anxious' Tatum back at Madison Square Garden with NBA East second seed on line
-
Strait of Hormuz traffic remains becalmed despite ceasefire
-
Melania Trump denies any links to Epstein abuse
-
American Airlines targets April 30 return to Venezuela
-
Venezuela police tear-gas protesters demanding salary rises
-
Robertson to leave Liverpool at end of season
-
Choudhary smashes Lucknow to dramatic IPL win over Kolkata
-
Sean 'Diddy' Combs asks US appeals court to overturn sentence
-
Verstappen Red Bull future in doubt as engineer to join McLaren
-
France's Macron in Rome for first meeting with Pope Leo
-
Angola name former Senegal boss Cisse as new coach
-
Sinner and Alcaraz wobble but advance to Monte Carlo quarter-finals
-
Reed soars to early Masters lead on wings of eagles
-
US Democrats fail in bid to curb Trump's Iran war powers
-
Veteran prop Slimani to return to France with Toulon
-
Iranians pay tribute to slain supreme leader weeks after killing
-
Russian police raid independent Novaya Gazeta media outlet
-
Barton Snow completes Cheltenham-Aintree double in Foxhunters Chase
-
IMF to cut global growth forecast due to Mideast war
-
Jihadists kill Nigerian troops including senior brigadier general
-
Local boy Aranburu sprints to Basque Country stage, Seixas extends lead
-
Russia brands Nobel Prize-winning rights group Memorial 'extremist'
-
England set for World Cup warm-up friendlies in Florida heat
-
Sabalenka pulls out of Stuttgart Open with injury
-
BTS kick off world tour with spectacular South Korea show
-
UK animal charity rescues over 250 dogs from single home
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
W.Morales--AT